このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Ensysce Biosciences マネジメント

マネジメント基準チェック /44

Ensysce Biosciences'の CEO はD. Kirkpatrickで、 Jan2009年に任命され、の在任期間は 15.42年です。の年間総報酬は$ 508.58Kで、 79.6%給与と20.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.021%を直接所有しており、その価値は$ 878.75 。経営陣と取締役会の平均在任期間はそれぞれ4.5年と3.8年です。

主要情報

D. Kirkpatrick

最高経営責任者

US$508.6k

報酬総額

CEO給与比率	79.6%
CEO在任期間	15.4yrs
CEOの所有権	0.02%
経営陣の平均在職期間	4.5yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

Ensysce Biosciences secures $8M convertible note financing

Jul 01

Ensysce Biosciences: Developing New Class Of Tamper-Proof Powerful Opioids

Dec 18

CEO報酬分析

Ensysce Biosciences の収益と比較して、D. Kirkpatrick の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$12m
Dec 31 2023	US$509k	US$405k	-US$11m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$623k	US$393k	-US$25m
Sep 30 2022	n/a	n/a	-US$30m
Jun 30 2022	n/a	n/a	-US$38m
Mar 31 2022	n/a	n/a	-US$31m
Dec 31 2021	US$288k	US$174k	-US$30m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$99k
Mar 31 2021	n/a	n/a	US$172k
Dec 31 2020	US$156k	US$156k	US$57k

報酬と市場: D.の総報酬 ($USD 508.58K ) は、 US市場 ($USD 673.68K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: D.の報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

D. Kirkpatrick (67 yo)

15.4yrs

在職期間

US$508,575

報酬

Dr. D. Lynn Kirkpatrick, Ph.D. is a Co Founder of ProlX Pharmaceuticals Corporation and has been its Chief Executive Officer since 1999. She has been Chief Executive Officer of Ensysce Biosciences, Inc. si...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
D. Kirkpatrick	President	15.4yrs	US$508.58k	0.021% $ 868.1
David Humphrey	CFO, Secretary & Treasurer	3.3yrs	US$441.95k	0.0027% $ 113.4
Geoffrey Birkett	Chief Commercial Officer	5.7yrs	US$392.35k	0% $ 0
Jeffrey Millard	Chief Operating Officer	less than a year	データなし	データなし
William Schmidt	Chairman of Clinical Advisory Board & Chief Medical Officer	8.4yrs	データなし	データなし
Linda Pestano	Chief Development Officer	2.7yrs	データなし	0% $ 0

4.5yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: ENSCの経営陣は経験豊富であると考えられます ( 4.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
D. Kirkpatrick	President	7.1yrs	US$508.58k	0.021% $ 868.1
William Schmidt	Chairman of Clinical Advisory Board & Chief Medical Officer	1.8yrs	データなし	データなし
Robert Gower	Independent Chairman of the Board	16.4yrs	US$47.60k	1.61% $ 66.5k
Lee Rauch	Independent Director	2.3yrs	US$29.17k	0% $ 0
Andrew Benton	Independent Director	4.5yrs	US$30.10k	0.26% $ 10.9k
Richard Dart	Member of the Clinical Advisory Board	no data	データなし	データなし
Steven Martin	Independent Director	3.8yrs	US$32.92k	0% $ 0
Lynn Webster	Member of the Clinical Advisory Board	no data	データなし	データなし
Hui-Chung Chang	Independent Director	8.4yrs	US$30.10k	0.41% $ 17.0k
Jeffrey Gudin	Member of the Clinical Advisory Board	no data	データなし	データなし
Curtis Rosebraugh	Independent Director	3yrs	US$25.42k	0% $ 0
Adam Levin	Independent Director	3yrs	US$27.92k	0% $ 0

3.8yrs

平均在職期間

67.5yo

平均年齢

経験豊富なボード: ENSCの取締役会は経験豊富であると考えられます ( 3.8年の平均在任期間)。

Ensysce Biosciences マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Ensysce Biosciences, Inc., Annual General Meeting, Aug 24, 2023

Independent Chairman of the Board recently bought US$182k worth of stock

High number of new directors

Ensysce Biosciences, Inc. Announces Chief Medical Officer Changes

Independent Chairman of the Board notifies of intention to sell stock

Ensysce Biosciences, Inc. Appoints William Chang as Director

Recent updates

Consensus revenue estimates decrease by 26%, EPS upgraded

No longer forecast to breakeven

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 16% to US$13.50

Ensysce Biosciences Receives Notice from The Nasdaq Stock Market Regarding Non-Compliance with Nasdaq Listing Rule 5550(a)(2)

Consensus EPS estimates fall by 32%

Price target decreased by 16% to US$11.33

Forecast to breakeven in 2026

Full year 2023 earnings released

Price target decreased by 13% to US$11.65

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

New minor risk - Profitability

Price target decreased by 13% to US$11.65

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

Ensysce Biosciences, Inc. has filed a Follow-on Equity Offering.

Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic

New major risk - Share price stability

Ensysce Biosciences, Inc. announced that it has received $1.7 million in funding

Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq

Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study

Consensus revenue estimates decrease by 21%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ensysce Biosciences, Inc. announced that it expects to receive $1.7 million in funding

Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study

Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol

Ensysce Biosciences, Inc., Annual General Meeting, Aug 24, 2023

Ensysce Biosciences Regains Compliance with the Equity Requirement in Nasdaq Listing Rule 5550(b)(1)

Consensus EPS estimates upgraded to US$9.75 loss, revenue downgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering.

Consensus revenue estimates increase by 14%

Price target decreased by 58% to US$29.40

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Chairman of the Board recently bought US$182k worth of stock

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $3.000002 million.

Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq

Ensysce Biosciences, Inc. Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study

Ensysce Biosciences, Inc. Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial

Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection

Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq

Consensus forecasts updated

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $4.06 million.

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $4.06 million.

Ensysce Biosciences Inc. Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A

Consensus revenue estimates fall by 33%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$240

High number of new directors

Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for Pf614

Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, A TAAP Abuse-Deterrent Oxycodone Extended-Release Product

Ensysce Biosciences, Inc. Announces First Subjects Dosed in Second Human Abuse Potential Study

Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR

Ensysce Biosciences, Inc. Announces Chief Medical Officer Changes

Ensysce Biosciences and Quotient Sciences Announce A Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, A Novel Opioid Designed to Prevent Abuse and Overdose

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Ensysce Biosciences, Inc. announced that it has received $8 million in funding

Independent Chairman of the Board notifies of intention to sell stock

Ensysce Biosciences secures $8M convertible note financing

Ensysce Biosciences, Inc. Appoints William Chang as Director

Ensysce Biosciences, Inc. Receives Non-Compliance Letter from Nasdaq Related to Bid Price

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ensysce Biosciences, Inc. Announces New Clinical Results from Trials PF614-102 and Pf614-MPAR-101

High number of new directors

Ensysce Biosciences, Inc., Annual General Meeting, Jun 23, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Ensysce Biosciences, Inc Appoints Lee Rauch to the Board of Directors

マネジメント基準チェック /44